

# Single or Repeat Zoledronate Versus Alendronate Following Denosumab (EUROpean Denosumab Effects Consolidation Study)

NCT05575167

---

**Status** RECRUITING  
**Sponsor** 424 General Military Hospital  
**Enrollment** 125 participants

## Key Eligibility Criteria

---

### Inclusion (1)

- Postmenopausal women treated with denosumab for 3 or more years who will reach osteopenia

### Exclusion (7)

- a bone disease other than postmenopausal osteoporosis
- use of medications other than bisphosphonates or SERMS affecting bone metabolism during the last 12 months before entering the study
- creatinine clearance  $<60$  mL/min/1.73 m<sup>2</sup>
- liver failure
- any type of cancer
- ... and 2 more (see full listing online)

## Locations (9 total)

---

Univ. Lille, CHU Lille, Lille, France  
251 Hellenic Airforce and VA General Hospital, Athens, Greece  
First Department of Propaedeutic and Internal Medicine, Medical School, National and Kapodistrian University of Athens, Athens, Greece  
... and 6 more locations